Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Epistemonikos ID: 771a194f793792cdf358baf25f8ed63452ca8344
First added on: Mar 25, 2026